drug
amoxicillin + vonoprazan fumarate
Marketedupdated 3mo agoby $PHAT Phathom Pharmaceuticals, Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval12 co-mentions · 6 sources
- drugVOQUEZNA DUAL PAK12 co-mentions · 6 sources
- tagSmall Molecule6 co-mentions · 6 sources
- drugVOQUEZNA6 co-mentions · 6 sources
- drugVOQUEZNA TRIPLE PAK6 co-mentions · 6 sources
- drugvonoprazan fumarate6 co-mentions · 6 sources
- drugamoxicillin6 co-mentions · 6 sources
- drugLarotid6 co-mentions · 6 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 49 investigational indications.
all catalysts(6)
approval · 6
May 3, 2022
approval
$PHAT9.2800-3.13%
VOQUEZNA DUAL PAK (AMOXICILLIN) — FDA approval
amoxicillin + vonoprazan fumarate
→
Aug 16, 2023
approval
$PHAT9.2800-3.13%
VOQUEZNA DUAL PAK (AMOXICILLIN) — FDA approval
amoxicillin + vonoprazan fumarate
→
May 1, 2024
approval
$PHAT9.2800-3.13%
VOQUEZNA DUAL PAK (AMOXICILLIN) — FDA approval
amoxicillin + vonoprazan fumarate
→
Jul 31, 2024
approval
$PHAT9.2800-3.13%
VOQUEZNA DUAL PAK (AMOXICILLIN) — FDA approval
amoxicillin + vonoprazan fumarate
→
Jun 12, 2025
approval
$PHAT9.2800-3.13%
VOQUEZNA DUAL PAK (AMOXICILLIN) — FDA approval
amoxicillin + vonoprazan fumarate
→
Oct 31, 2025
approval
$PHAT9.2800-3.13%
VOQUEZNA DUAL PAK (AMOXICILLIN) — FDA approval
amoxicillin + vonoprazan fumarate
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 3, 2027
258 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Aug 11, 2030formulationUS 91864114.0y
- Apr 10, 2030compositionUS 79774883.6y
FDA exclusivities (2)
- May 3, 2032GAINGAIN Antibiotic (5y)
- May 3, 2027NCENew Chemical Entity (5y)258d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that